Upadacitinib治疗特应性皮炎、白癜风和斑秃三联征患者：病例报告和文献综述
Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review.
摘要(中文译文)
重度特应性皮炎（AD）、白癜风和斑秃（AA）同时发生于同一患者极为罕见，并构成重大的治疗挑战，因为传统的“疾病特异性”治疗往往疗效欠佳。新出现的证据表明，JAK-STAT信号通路在这些疾病的发病机制中共同发挥作用，提示靶向“多病共治”策略的潜力。一名57岁男性表现为重度、治疗难治性AD、广泛性白癜风和AA。在传统治疗失败后，开始使用选择性JAK1抑制剂乌帕替尼（每日15 mg）治疗。观察到快速且显著的改善：瘙痒在数日内消退，AD相关红斑在15周时大幅清除，眉毛在数月内完全再生，且在一年随访时白癜风皮损出现明显的色素再生。治疗耐受性良好。本病例提示，乌帕替尼单药治疗可能是重度共存AD、白癜风和AA的一种有效且耐受性良好的选择。它为新型“多病共治”范式提供了临床证据，该范式靶向共同的致病通路而非单个疾病表型，为管理复杂的免疫介导共病提供了新的策略方向。
Abstract
The simultaneous occurrence of severe atopic dermatitis (AD), vitiligo, and alopecia areata (AA) in a single patient is exceptionally rare and poses a significant therapeutic challenge, as conventional "disease-specific" therapies often yield suboptimal results. Emerging evidence implicates the shared JAK-STAT signaling pathway in the pathogenesis of these conditions, suggesting the potential for a targeted "multi-disease therapy" approach. A 57-year-old man presented with severe, treatment-refractory AD, extensive vitiligo, and AA. Following the failure of conventional therapies, treatment with the selective JAK1 inhibitor upadacitinib (15 mg daily) was initiated. A rapid and marked improvement was observed: pruritus subsided within days, AD-related erythema cleared substantially by 15 weeks, complete eyebrow regrowth occurred within months, and significant repigmentation of vitiligo lesions was evident at one-year follow-up. The treatment was well-tolerated. This case suggests that upadacitinib monotherapy may be an effective and well-tolerated option for severe co-existing AD, vitiligo, and AA. It provides clinical evidence supporting the novel "multi-disease therapy" paradigm, which targets common pathogenic pathways rather than individual disease phenotypes, offering a new strategic direction for managing complex immune-mediated comorbidities.
如何引用
AMA
Tao Wang, Xiaofang Zhang, Jingping Wang, Kaiwen Zhuang, Tingting Wang. Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review.. Frontiers in immunology. 2026; doi:10.3389/fimmu.2026.1795986.
APA
Tao Wang, Xiaofang Zhang, Jingping Wang, Kaiwen Zhuang, Tingting Wang (2026). Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1795986
GB/T 7714
Tao Wang, Xiaofang Zhang, Jingping Wang, Kaiwen Zhuang, Tingting Wang. Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review.[J]. Frontiers in immunology, 2026 doi:10.3389/fimmu.2026.1795986.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出